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com (A.T. Yazici).Abdullah Ozkaya ⇑; Zeynep Alkin; Ihsan Yilmaz; Ahmet Taylan YaziciAbstractBackground and objective: To compare the efficacy of intravitreal ranibizumab (IVR) for the treatment of neovascular age-related
macular degeneration (nAMD) between phakic and pseudophakic eyes after a follow-up of two years.
Materials and methods: Data were analyzed retrospectively. The newly diagnosed and treatment naïve nAMD patients were
included in the study. The patients were divided into two subgroups: phakic group, and pseudophakic. All patients received 3
consecutive monthly IVR injections, and then the treatment was continued on an as-needed regimen. Patients were examined
monthly, and the data at the baseline, at month 6, 12, 18, and 24 were evaluated. The changes in best corrected visual acuity
(BCVA), central retinal thickness (CRT), and the number of injections were compared between the two groups.
Results: The study included 92 eyes of 87 patients (58 phakic, 34 pseudophakic). Mean logarithm of the minimal angle of resolu-
tion (LogMAR) VA at the baseline, and at month 6, 12, 18, and 24 was 0.89, 0.74, 0.75, 0.73, and 0.75, in the phakic group; and
0.79, 0.71, 0.66, 0.70, and 0.70 in the pseudophakic group, respectively. The change in mean BCVA from the baseline to month 6,
12, 18, and 24 was not statistically different between the two groups (p = 0.4, p = 0.9, p = 0.5, p = 0.6, respectively). Mean injec-
tion number at month 24 was 7.9 and 8.1 in the phakic and pseudophakic group, respectively (p = 0.7).
Conclusion: Intravitreal ranibizumab treatment on an as-needed treatment regimen is effective in preserving vision and improving
central retinal thickness in both the phakic and pseudophakic group of nAMD patients. The functional and anatomical outcomes of
the treatment, and the number of injections were similar in the phakic and pseudophakic nAMD patients after a follow-up time of
24 months.
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Neovascular age-related macular degeneration (nAMD) is
the leading cause of severe visual loss among elderly popula-
tion in developed countries.1,2 Before the era of intravitrealanti-vascular endothelial growth factor (anti-VEGF) therapy,
only prevention for visual loss might have been achieved in
a limited number of nAMD patients with different treatment
options.3–8 The introduction of bevacizumab (full length anti-
body against VEGF-A) and ranibizumab (Fab part of antibodye:
al.com
l.: +90
gmail.
Ranibizumab in phakic vs pseudophakic nAMD patients 183against VEGF-A) has led the vast majority of the patients to
preserve the baseline visual acuity (VA) and gave the chance
of visual improvement to at least one third of the nAMD
patients.9,10 The multicenter studies showed that rani-
bizumab was effective to prevent VA loss up to 95% of the
patients, and was effective to make an improvement in VA
up to 40% of the patients.10–13 These studies were mainly effi-
cacy and dosing regimen studies, therefore they did not
focus on lens status.
Recently, three studies were published about the effect of
lens status on the treatment of nAMD with ranibizumab.14–16
One of these studies was a meta-analysis of the patient data
from ANCHOR and MARINA studies,14 and the two other
studies were retrospective single center studies.15,16 No
visual or anatomical differences were found between the
phakic and pseudophakic eyes in these three studies.14–16
Hereditary factors, environmental factors, and ocular fac-
tors such as age-related alterations of the retina, inflamma-
tory reactions, and the effect of free radicals are thought to
be responsible for the pathogenesis of AMD.17 In some
experimental studies it was shown that excessive levels of
white light exposure may induce the apoptosis of the photo-
receptors.18,19 Therefore the effect of cataract extraction on
the progression of AMD is evaluated in many studies.17,20–
25 In most of the studies, it was suggested that cataract sur-
gery may increase the development and progression of
AMD.20–25 This phenomenon was attributed to increased
light toxicity, increased inflammation, and postoperative cys-
toid macular edema after cataract surgery.17 However, there
is still an ongoing debate about whether the cataract surgery
has any effect on progression of AMD.25 Many anatomical
and biochemical changes occur in the vitreous after cataract
surgery.26,27 In addition, it is reported that posterior vitreous
detachment (PVD) was induced after cataract surgery, and
the presence of PVD was found to be related with increased
retinal penetration of bevacizumab in rabbit eyes.28 In regard
to these findings we hypothesized that all of these changes
after cataract surgery may affect the outcomes of IVR treat-
ment for nAMD in pseudophakic patients and since there is
a little amount of data on this topic, we aimed to compare
the efficacy of IVR on an as-needed regimen between phakic
and pseudophakic nAMD patients.Materials and methods
In this retrospective, comparative study, we reviewed the
records of the nAMD patients who had a baseline VA
between 1.8 and 0.3 LogMAR and treated with intravitreal
ranibizumab injection on an as-needed treatment regimen
between January 2009 and January 2011. A written informed
consent for the treatment was obtained from all patients
before the treatment, and the study adhered to the tenets
of the Declaration of Helsinki.
To be included in the study, each patient was required to
have all of the following criteria; age P50 years, a best cor-
rected VA (BCVA) between LogMAR 1.8 and 0.3, to be newly
diagnosed as nAMD and treatment naive, and a minimum fol-
low-up time of 24 months. Patients were not included in the
study if they had a retinal disease other than nAMD, or if they
had received previous intravitreal injection, or photodynamic
therapy for nAMD, or if they had diagnosed as polypoidal
choroidal vasculopathy, or retinal angiomatous proliferation,or if they were treated with other retreatment regimens, or if
all of the follow-up data were not available. Also, the phakic
patients who underwent cataract surgery during the follow-
up time were excluded from the study. The patients were
divided into two groups according to their lens state which
were phakic and pseudophakic groups at the initial diagno-
sis. All the pseudophakic patients had undergone uneventful
phacoemulsification surgery and had intact posterior cap-
sules. The pseudophakic patients who were included had
undergone cataract surgery at least 6 months before the
beginning of the IVR treatment.
Data collected from the patients’ records included age,
gender, choroidal neovascularization (CNV) type (predomi-
nantly classic or minimal classic/occult), BCVA and central ret-
inal thickness (CRT) at baseline, month 6, month 12, month
18, and month 24. The total number of injections at month
12 and 24 was also recorded.
The included patients underwent a standardized examina-
tion including measurement of BCVA (visual acuity was mea-
sured as Snellen lines then converted to LogMAR for
statistical analyses), slit-lamp biomicroscopy, intraocular
pressure (IOP) measurement via applanation tonometry,
and fundus examination. Fundus photography, fluorescein
angiography (FA) (HRA-2; Heidelberg Engineering, Heidel-
berg, Germany), and optical coherence tomography (OCT)
imaging (Stratus OCT TM; Carl Zeiss Meditec Inc., Dublin,
CA, USA.) were performed before treatment. All examina-
tions were repeated monthly, except FA. Fluorescein angiog-
raphy was repeated only when the cause of VA deterioration
could not be clarified with the other methods. Optical coher-
ence tomography was used for detecting subretinal fluid and
measurement of CRT. Central retinal thickness, defined as
the mean thickness of the neurosensory retina in a central
1 mm diameter area, was computed using OCT mapping
software generated by the device.
All injections were performed under sterile conditions
after topical anesthesia, 10% povidone-iodine (Betadine; Pur-
due Pharma, Stamford, CT) scrub was used on the lids and
lashes, and 5% povidone-iodine was administered on the
conjunctival sac. Intravitreal ranibizumab (Lucentis; Novartis,
Basel, Switzerland) was injected through the pars plana at
3.5 mm posterior to the limbus with a 30-gauge needle.
Patients were instructed to return to the hospital if they expe-
rienced decreased vision, eye pain, or any new symptoms.
Initially, all patients received a loading dose of three con-
secutive monthly IVR injections (0.5 mg/0.05 ml). Then the
patients were followed monthly, and a single injection of
IVR was repeated when the VA decreased by one or more
ETDRS lines from the last visit, or newly developed macular
hemorrhage, or evidence of subretinal fluid on OCT. The fol-
low-up visits of the patients were performed by two physi-
cians who had the same clinical practice patterns (AO, ATY).
Primary outcome measures of this study included the
change in BCVA and OCT defined CRT from baseline to
months 6, 12, 18, and 24. Secondary outcome measures were
the total number of injections at months 12 and 24, and the
complications of intravitreal injections.Statistical analysis
Visual acuity was converted to the logarithm of the mini-
mum angle of resolution (LogMAR) for statistical analysis.
Figure 1. Changes in mean visual acuity in the phakic and pseudophakic
groups. The graph shows the mean LogMAR visual acuity levels from
baseline to 24 months. The p values for phakic versus pseudophakic
groups at each time point.
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centages, while numerical variables were expressed as the
mean and standard deviation. The baseline characteristics
and outcome measures between the groups were compared
using the Chi-square test for categorical variables and inde-
pendent sample test or Mann–Whitney test for numerical
variables. The statistical evaluation was performed using
SPSS (Version 16.0, SPSS Inc., Chicago, IL, USA). A p value
of less than 0.05 was considered to be statistically significant.
Results
Ninety-two eyes of 87 patients met the inclusion criteria
for the study. The mean age of the patients was
73.5 ± 7.8 years (range 53–89 years). Forty-two patients
(48.3%) were male, 45 patients (51.7%) were female. Pre-
dominantly classic CNV was present in 21 eyes (22.8%), and
occult/minimally classic CNV was present in 71 eyes
(77.2%). The mean number of injections at month 12, and
24 was 5.4 ± 1.5 (range 3–8), and 8.0 ± 2.9 (range 3–15).
Fifty-eight eyes (63.0%) were phakic, and 34 eyes (37.0%)
were pseudophakic. The general characteristics of the two
groups were similar (Table 1).
The mean BCVA of the phakic and pseudophakic patients
at baseline was 0.89 ± 0.44 and 0.79 ± 0.44 LogMAR, respec-
tively. There was not a significant difference between the
mean BCVA levels of the groups at all of the study visits
(p > 0.05 for all, Table 2, Fig. 1). In addition, the change in
mean BCVA from baseline to months 6, 12, 18, and 24 was
statistically different in both the groups (p = 0.004,
p = 0.01, p = 0.009, p = 0.02, respectively for the phakic
group; p = 0.007, p = 0.01, p = 0.03, p = 0.03, respectively
for the pseudophakic group). However, the change in the
mean BCVA from baseline to months 6, 12, 18, and 24 was
not statistically different between the two groups (p = 0.4,
p = 0.9, p = 0.5, p = 0.6, respectively).
At month 24, 20 eyes (34.4%) in the phakic group and 13
eyes (38.2%) in the pseudophakic group had gained VAP 3
lines (p = 0.2). Fifty eyes (86.2%) in the phakic group and 28
eyes (82.3%) in the pseudophakic group had stable orTable 1. Baseline characteristics of the two groups.
Phakic group
Mean age 72.4 ± 7.1 years (range 53–85 years)
Gender (F/M) 21/32
CNV type (O/C) 11/47
F, female; M, male; R: right eye; L, left eye; CNV, choroidal neovascularization; O, occult;
Table 2. LogMAR visual acuity values and CRT findings in microns in the phak
Variables Phakic
Baseline visual acuity, mean 0.89 ± 0.44 (range 0.3–1.8)
Month 6 visual acuity, mean 0.74 ± 0.37 (range 0.1–1.5)
Month 12 visual acuity, mean 0.75 ± 0.42 (range 0.1–1.7)
Month 18 visual acuity, mean 0.73 ± 0.44 (range 0.2–2.1)
Month 24 visual acuity, mean 0.75 ± 0.45 (range 0.2–2.1)
Baseline CRT, mean 322 ± 99 l (range 198–681)
Month 6 CRT, mean 272 ± 83 l (range 155–553)
Month 12 CRT, mean 258 ± 65 l (range 150–443)
Month 18 CRT, mean 257 ± 61 l (range 156–403)
Month 24 CRT, mean 264 ± 73 l (range 146–429)
CRT: central retinal thickness, LogMAR: logarithm of the minimum angle of resolution, vs:improved vision (loss of <3 line, or remained stable, or
gained P1 lines) (p = 0.7). Eight eyes (13.8%) in the phakic
group and 6 eyes (17.6%) in the pseudophakic group had loss
of VAP 3 lines (p = 0.7).
The mean CRT of the phakic and pseudophakic patients at
baseline was 322 ± 99 and 333 ± 89 microns, respectively.
There was not a significant difference between the mean
CRT levels of the two groups at all of the study visits
(p > 0.05 for all, Table 2, Fig. 2). In addition, the change in
mean CRT from the baseline to months 6, 12, 18, and 24
was statistically different in both the two groups (p = 0.001,
p = 0.0001, p = 0.0001, p = 0.002, respectively for the phakic
group; p = 0.0001, p = 0.0001, p = 0.001, p = 0.001, respec-
tively for the pseudophakic group). However, the change in
mean CRT from the baseline to months 6, 12, 18, and 24
was not statistically different between the two groups
(p = 0.2, p = 0.4, p = 0.5, p = 0.5, respectively).
The total number of injections at month 12 was 5.4 ± 1.3
(range 3–8) in the phakic group and 5.4 ± 1.7 (range 3–8) in
the pseudophakic group (p = 0.8), and the total number of
injections at month 24 was 7.9 ± 2.5 (range 3–14) in thePseudophakic group P value
75.4 ± 8.6 years (range 54–89 years) 0.08
21/13 0.06
10/24 0.3
C, classic.
ic and pseudophakic groups at different time points.
Pseudophakic Phakic vs pseudophakic p values
0.79 ± 0.44 (range 0.4–1.8) 0.2
0.71 ± 0.52 (range 0.1–2.1) 0.7
0.66 ± 0.52 (range 0.0–2.1) 0.3
0.70 ± 0.57 (range 0.0–2.1) 0.7
0.70 ± 0.56 (range 0.0–2.1) 0.6
333 ± 89 l (range 174–516) 0.6
253 ± 63 l (range 165–463) 0.2
250 ± 58 l (range 178–414) 0.5
251 ± 67 l (range 151–483) 0.6
258 ± 69 (range 139–425) 0.6
versus, l: microns.
Figure 2. Changes in mean central retinal thickness in the phakic and
pseudophakic groups. The graph shows the mean central retinal thickness
levels from baseline to 24 months. The p values for phakic versus
pseudophakic groups at each time point.
Ranibizumab in phakic vs pseudophakic nAMD patients 185phakic group and 8.1 ± 3.5 (range 3–15) in the pseudophakic
group (p = 0.7).
No serious complications such as endophthalmitis, vitre-
ous hemorrhage, and retinal detachment were observed in
any of the patients. Only mild complications such as punctu-
ate keratitis (10.5% in phakic group, 15% in pseudophakic
group, p = 0.2) subconjunctival hemorrhage (8.7% in phakic
group, 7.5% in pseudophakic group, p = 0.7), transient mild
anterior uveitis (3.5% in phakic group, 5.0% in pseudophakic
group, p = 0.6) were detected.
Discussion
Although the effect of cataract surgery on the progression
of AMD is widely studied, there are only three studies which
compare the efficacy of intravitreal anti-VEGF agents
between phakic and pseudophakic patients.14–16 The results
of our study are consistent with these previous studies; there
are a few differences in regard to visual acuity cut-off points
and treatment protocol details.14–16
In a study by Baek et al.,15 intravitreal ranibizumab on an
as-needed treatment regimen was found to be effective in
both phakic and pseudophakic patients. In the study it was
reported that, the anatomical and visual outcomes were sim-
ilar between the two groups after a mean follow-up period of
18 months. The mean injection number of the phakic and
pseudophakic group was reported to be 3.87 and 3.62,
respectively and was reported not to be statistically different.
Also the possible effect of posterior vitreous detachment on
the intravitreal ranibizumab treatment was mentioned in the
study. However, this relationship was not evaluated, and it
is announced that the authors were evaluating this relation-
ship in an ongoing study.15 The visual and anatomical out-
comes of our study are similar to the study by Baek et al.
The mean injection number was very low in the study by Baek
et al. This may be due to one of the retreatment criteria of
this study which was ‘‘visual loss’’. At the present, only one
line of visual acuity loss is considered as a retreatment crite-
rion, however in the study by Baek et al., the visual acuity cri-
terion for retreatment was considered as loss of two or more
lines.
In a meta-analysis of individual patient data from the
ANCHOR and MARINA studies, the outcomes of monthly
ranibizumab treatment were compared between the phakic
and pseudophakic patients.14 In the study 243 phakic and179 pseudophakic eyes from the ANCHOR study, and 385
phakic and 330 pseudophakic eyes from the MARINA study
were evaluated. No visual or anatomical differences were
found between the phakic and pseudophakic eyes in the
study.14
In a more recent study by Ozkaya et al.,16 the treatment
outcomes of as-needed ranibizumab treatment were com-
pared between the phakic and pseudophakic groups of
nAMD patients with a good baseline visual acuity. The results
of the study were similar to our study and no difference was
found between the two groups in regard to visual and ana-
tomical outcomes.
Although the results of our study are consistent with the
previous three studies; there are a few differences in regard
to visual acuity cut-off points and treatment protocol details.
In a more recent study, the effect of posterior vitreous
detachment on the intravitreal bevacizumab or ranibizumab
treatment was evaluated by Üney et al.29 They reported that
the patients with posterior vitreous detachment had better
visual outcomes than the patients with attached posterior
vitreous.
In this study, intravitreal ranibizumab on as-needed treat-
ment regimen was found to be effective in both phakic and
pseudophakic group of patients. There was not a statistically
significant difference in improvement of BCVA and CRT, and
the mean injection numbers between the two groups. These
results may show that the therapeutic effect of intravitreal
ranibizumab treatment does not change after cataract
extraction in this subgroup of patients, and both phakic
and pseudophakic patients may equally benefit from this
therapy. This may be attributable to different mechanisms.
It is conventionally thought that the presence of cataract
has a protective effect on the progression of nAMD and it
is a known fact that PVD is induced after cataract surgery in
up to 60% of the patients, on the other hand in some studies
it is reported that the therapeutic effects of intravitreal injec-
tions were better in the presence of PVD.27,29 The results of
our study may be explained by the combination of these data
and it may be proposed that the presence of PVD may offset
the negative effects of cataract surgery on the progression of
nAMD.
The main limitation of the study was the retrospective
design. Also we used a time domain OCT device and the inci-
dence of posterior vitreous detachment was not evaluated in
the patients. The time domain OCT guided as-needed treat-
ment regimens may not be as effective as spectral domain
OCT guided as-needed treatment regimens because of the
difference between the resolutions of the devices, therefore
this was a limitation. The powerful sides were the relatively
long follow-up time and the similarity of baseline characteris-
tics in the two groups. Randomized controlled studies includ-
ing the other variables such as the presence of posterior
vitreous detachment, and the factors that may affect the final
visual outcomes would be necessary in this subgroup of
patients.
In conclusion, the results of this study imply that the ther-
apeutic effects of IVR treatment were similar in both of the
pseudophakic and phakic group of nAMD patients.Conflict of interest
The authors declared that there is no conflict of interest.
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